Elsevier to expand its suite of solutions to cover the entire drug discovery and development value chain by launching new life sciences solutions.
Formed in 2002, Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets. This content enables researchers to identify the most promising compounds, repurpose existing compounds and identify targets with which the new compounds might interact.
"The acquisition of Aureus Sciences provides us with tremendous opportunities to generate more value for our customers," said Mark van Mierle, Managing Director Elsevier Pharmaceutical and Biotech Group. "With the combination of Aureus content assets and the content already available by Elsevier, we can create a valuable solution for those in need of improving speed and accuracy of lead-finding, decision-making and other key processes."
The acquisition enables the combination of high quality and deeply extracted content from both companies to launch new solutions for our Pharmaceutical and Biotech customers. The first evidence of this will be seen early this year with the release of a new medicinal chemistry solution.
"The integration of Aureus into Elsevier, and the consolidation of best in class content, will complement Elsevier's leadership in biomedical disciplines and strengthen our ability to offer new innovative databases to researchers in medicinal chemistry and pharmacology," said Jason Theodosiou, CEO of Aureus Sciences. "We will see many positive synergies resulting from this combination."
The acquisition is effective immediately and financial terms of the transaction are not being disclosed.